RACGP Guidelines for IMGs: Complete AMC MCQ Prep Guide (2026)

Last reviewed: May 2026 | Written by the MplusX Editorial Team

---

---

It is one of the most common ways candidates lose easy marks on the AMC MCQ.

A question presents a healthy, asymptomatic 46-year-old patient who has come to your clinic for a routine checkup. The patient asks if they should undergo screening for bowel cancer. The vignette notes that there is no family history of colorectal cancer.

You recall that bowel screening typically starts at age 50 in many international guidelines, so you advise the patient to return in four years.

The screen flashes red.

Incorrect.

Under the updated Australian National Bowel Cancer Screening Programme (NBCSP) guidelines, screening now begins at age 45 (updated in 2024). The correct answer is to initiate screening using an immunochemical faecal occult blood test (iFOBT) immediately.

To pass the AMC MCQ, you must master the preventive and screening frameworks defined by the Royal Australian College of General Practitioners (RACGP). These guidelines, compiled in the famous RACGP “Red Book,” represent a major portion of the exam’s preventive medicine and public health questions.

This guide outlines the high-yield RACGP screening rules, chronic disease planning systems, and risk calculators you must memorize to secure these marks.

---

Why the RACGP “Red Book” is Essential for the AMC MCQ

The AMC MCQ exam is designed to ensure you can function safely as an entry-level doctor in the Australian healthcare system. A massive part of Australian healthcare is preventive medicine and early detection in primary care.

Rather than waiting for patients to present with advanced disease, the Australian system utilizes structured, national screening programs to catch conditions early.

The RACGP “Red Book” outlines the screening intervals, age thresholds, and diagnostic pathways for: 1. Oncology Screening: Bowel, cervical, and breast cancer screening. 2. Cardiovascular Prevention: Absolute cardiovascular disease risk assessment and management. 3. Metabolic Screening: Type 2 diabetes screening thresholds. 4. Osteoporosis and Bone Health: Screening and diagnostic DEXA scan thresholds.

When the AMC examiners write questions about “the next step in management” for an asymptomatic patient, the correct option is almost always pulled directly from the Red Book recommendations.

---

National Screening Program Reference Matrix

Use this master reference matrix to memorize standard screening thresholds and positive-result pathways:

Screening Program	Target Population	Screening Test	Age Range	Frequency	Management of Positive Result	High-Risk Screening Exception
Bowel Cancer (NBCSP)	Asymptomatic average-risk individuals	iFOBT (Faecal Occult Blood)	45 to 74	Every 2 years	Refer for colonoscopy (do not repeat iFOBT)	First-degree relative diagnosed with CRC <55: Colonoscopy every 5 years starting at age 40 (or 10 years younger than relative).
Cervical Cancer (NCSP)	Anyone with a cervix, screen-active	Primary HPV PCR Test (Clinician or Self-Collect)	25 to 74	Every 5 years	If HPV positive (non 16/18): reflex cytology. If HPV 16/18 positive: refer directly for colposcopy.	Symptomatic (post-coital/intermenstrual bleeding): bypass screening, perform clinician cytology and refer for specialist gynaecology review.
Breast Cancer	Asymptomatic women, average-risk	Screening Mammography	50 to 74	Every 2 years	Refer to BreastScreen assessment clinic for diagnostic ultrasound/biopsy	Strong family history (multiple pre-menopausal cases): annual mammography starting at age 40, potentially with annual MRI.
Osteoporosis Screening	Men and postmenopausal women	DEXA Scan (Dual-Energy X-ray Absorptiometry)	Men >70, Women >65	Based on T-score severity	If T-score <= -2.5: initiate antiresorptive therapy (bisphosphonates)	Younger patients with risk factors (prolonged oral corticosteroids >=3 months, early menopause <45, rheumatoid arthritis, endocrine conditions): perform diagnostic DEXA early.

• 25: Cervical Screening Starts HPV PCR every 5 years
• 45: Bowel Screening Starts iFOBT every 2 years
• 50: Breast Screening Starts Mammography every 2 years
• 74: Screening Programs End Transition to individual assessment

---

1. National Cancer Screening Programs: The High-Yield Rules

You can expect multiple questions on your exam testing the exact age brackets, frequencies, and tests used for Australia’s national cancer screening programs.

High-Yield Cancer Screening Traps to Watch Out For:

• Bowel Screening Age: Ensure your study materials reflect that screening starts at 45, not 50. The National Bowel Cancer Screening Programme transitioned the start age down to 45 in 2024 to combat rising early-onset colorectal cancer.
• Positive iFOBT: If a patient’s screening iFOBT is positive, the next step is always a colonoscopy. Do not repeat the iFOBT. Do not order a CT colonography or virtual colonoscopy as the primary next step.
• Cervical Self-Collection: In Australia, self-collected vaginal swabs are now offered as an option to all eligible screen-active individuals (ages 25–74) for their cervical screen. It is clinically equivalent in sensitivity to a clinician-collected cervical sample for detecting HPV.
• Pap Smears Are History: If a question option mentions “schedule a Pap smear,” it is outdated. The Australian screening program uses primary HPV DNA testing via PCR, not cytology (Pap smears), as the initial screening tool. Cytology is only performed as a reflex test if HPV is detected.

---

2. Chronic Disease Care: The GPCCMP Framework

In older study materials and textbooks, you will find references to the GP Chronic Condition Management Plan (GPCCMP) (GPCCMP – GPCCMP) and GPCCMP (GPCCMP – GPCCMP).

For the 2026 exam cycle, these terms are obsolete. They have been replaced by a single, integrated chronic disease care framework: the GP Chronic Condition Management Plan (GPCCMP).

A GPCCMP is designed for patients with at least one chronic medical condition that has been present (or is likely to be present) for 6 months or longer. This includes conditions like Type 2 diabetes, asthma, COPD, chronic kidney disease, and cardiovascular disease.

Allied Health Visits Allocation under the GPCCMP

When a patient is managed under an active GPCCMP, they are eligible for Medicare-subsidized referrals to allied health professionals for up to 5 visits per calendar year. These 5 visits are shared across referrable disciplines depending on clinical need: * Podiatry: High priority for diabetic foot checks, neurovascular screening, and wound care. * Physiotherapy / Exercise Physiology: For chronic musculoskeletal pain, osteoarthritis, or cardiac/COPD rehabilitation. * Dietetics / Diabetes Education: For metabolic optimization in Type 2 diabetes, fatty liver disease, or chronic kidney disease.

Step-by-Step Coordination Workflow

1. Identification & Assessment: The General Practitioner (GP) or Practice Nurse identifies the chronic condition. A comprehensive review is conducted, recording the patient’s medical history, current medications, self-management capacity, and clinical targets (e.g., HbA1c <7.0%, BP <130/80 mmHg). 2. Creation of the Plan: The GP, in consultation with the patient, drafts the GPCCMP. This outlines the treatment goals, patient actions, and emergency safety-net parameters. 3. Allied Health Referrals: The GP completes the referrals for the 5 visits. 4. Review Loop: The GPCCMP must be reviewed every 6 months (or earlier if clinical needs change) to monitor progress, repeat essential lab diagnostics, and adjust therapies.

---

3. Absolute Cardiovascular Disease Risk Assessment

Australia does not assess single risk factors (like high cholesterol or high blood pressure) in isolation. Instead, the RACGP guidelines mandate assessing a patient’s Absolute Cardiovascular Disease (CVD) Risk.

This approach calculates the numerical probability of a patient experiencing a cardiovascular event (myocardial infarction or stroke) within the next 5 years using the Australian Cardiovascular Risk Calculator (AusCVDRisk).

Risk Categories and Management (AusCVDRisk 2026 Guidelines):

* Low Risk (<5% probability over 5 years): Focus on lifestyle modification (diet, exercise, smoking cessation). Reassess in 5 years. * Intermediate Risk (5% to 10% probability): Implement intensive lifestyle modification. Reassess in 2 years. Consider initiating pharmacotherapy (statin + antihypertensive) if lifestyle measures fail after 3 to 6 months, or if additional risk-enhancing features are present (e.g., family history of premature CVD, severe obesity). * High Risk (>=10% probability): Initiate pharmacotherapy immediately (statin + antihypertensive) alongside lifestyle advice. Do not delay for a trial of lifestyle changes.

Target Dosing and Refractory Dwell-Points

When managing high-risk patients, the target parameters are strict: * Blood Pressure Target: Target <130/80 mmHg for patients with diabetes or chronic kidney disease. * Lipid Target (LDL-C): Target <1.8 mmol/L for high-risk individuals, and <1.4 mmol/L for patients with established secondary CVD. * Refractory Management: If LDL-C remains above target despite maximum tolerated dose of a high-intensity statin (atorvastatin 80mg or rosuvastatin 40mg), add ezetimibe 10mg daily. If targets are still not met and the patient has established secondary cardiovascular disease, refer for PCSK9 inhibitor evaluation. — Reading about MplusX review might also be helpful.

Case Study: The 45-Year-Old Health Assessment

Let us explore how an Australian General Practitioner applies these RACGP guidelines to an asymptomatic patient presenting for their first major health check.

The Patient Profile

Dr. Alistair, a GP in suburban Brisbane, is scheduled to see John, a 45-year-old accountant. John has no specific medical complaints but notes his father had a “minor heart attack” at age 62. John smokes 10 cigarettes daily, drinks 3-4 beers on weekends, and has a sedentary lifestyle.

The Step-by-Step Assessment Workflow

1. Administrative Registration & Eligibility: * John is aged 45, making him eligible for the Medicare-subsidized 45–49 Year Old Health Assessment. This dedicated consultation is designed to identify chronic disease risk factors before they cause end-organ damage. 2. Screening Checks & Measurements: Obesity:* Measure height, weight, waist circumference, and calculate BMI (John’s BMI is 29.5 kg/m², waist is 104 cm). Reading about AMC MCQ final revision plan might also be helpful. Hypertension:* Check blood pressure (John’s BP is 138/86 mmHg). Type 2 Diabetes:* Calculate the AUSDRISK score. Because his score is high (>12), order a fasting blood glucose or HbA1c. Bowel Cancer Screening:* John has just reached age 45. Explain the National Bowel Cancer Screening Program. Provide him with the iFOBT home test kit instructions, advising him to complete the screening every 2 years. 3. Absolute CVD Risk Calculation (AusCVDRisk): * Calculate John’s 5-year absolute CVD risk using his age (45), blood pressure (138/86), smoking status (active smoker), and a lipid panel (to be ordered). High-Risk Check:* John does not automatically qualify as high risk (father’s MI was at 62, which is not premature; premature is defined as first-degree male relative <55 or female relative <65). 4. Diagnostics & Screening Referrals: * Order FBG/HbA1c and Lipid Profile. * Perform a baseline screening ECG if John complains of atypical chest discomfort (asymptomatic patients do not require screening ECGs). 5. Lifestyle Counseling & Safety-Netting: * Provide smoking cessation support (pharmacotherapy options: nicotine replacement therapy or varenicline/bupropion). * Advise on exercise targets (150–300 minutes of moderate-intensity physical activity weekly). * Schedule a follow-up appointment in 1 week to review lab results, calculate final CVD risk score, and initiate pharmacotherapy if needed.

---

How to Study the RACGP Guidelines Efficiently

The RACGP Red Book is a massive document, but you do not need to read it cover to cover. Focus your preparation on these high-yield study actions:

1. Focus on Screening Transitions: Memorize the exact ages when screening programs start and stop. These are tested directly in age-based health assessment scenarios (e.g., the 45–49 year old health check). 2. Understand High-Risk Exceptions: Screening intervals change for patients with a family history. For example, if a patient has a first-degree relative diagnosed with colorectal cancer before age 55, they do not undergo standard iFOBT screening. Instead, they require screening colonoscopies every 5 years, starting at age 40 (or 10 years younger than the age of the youngest affected relative). 3. Master the Immunisation Schedule: The National Immunisation Program (NIP) schedule is highly tested. Pay attention to childhood vaccination milestones (birth, 2, 4, 6, 12, 18 months, and 4 years) and adult vaccination updates (Pneumococcal and Shingrix shingles vaccines for elderly patients).

---

Frequently Asked Questions

What is the difference between the Red Book and the Green Book?

The RACGP Red Book focuses on preventive activities (screening, immunizations, and risk assessments for asymptomatic patients). The Green Book focuses on lifestyle risk factors (smoking, nutrition, alcohol, and physical activity counseling). For the AMC MCQ, the Red Book is significantly higher yield, particularly the chapters on cancer screening and cardiovascular risk.

At what age does cervical cancer screening stop in Australia?

Under the National Cervical Screening Program (NCSP), screening stops between the ages of 70 and 74. A patient is eligible to exit the program if they are aged 70 to 74 and have had two consecutive negative HPV tests in the last 10 years. If they have not had regular screens, they must undergo exit screening.

What is the threshold for screening for Type 2 diabetes under RACGP guidelines?

Screening for Type 2 diabetes should be performed every 3 years starting at age 45 using the AUSDRISK score. For Aboriginal and Torres Strait Islander peoples, screening should start much earlier, at age 18, reflecting the higher prevalence of early-onset metabolic disease in these populations.

How does familial history alter breast cancer screening guidelines?

Asymptomatic women with no family history undergo screening mammograms every 2 years from ages 50 to 74. Women with a strong family history (multiple first-degree relatives with pre-menopausal breast or ovarian cancer) are classified into high-risk categories and may require annual mammograms starting at age 40, potentially combined with annual breast MRI scans.

Who is eligible for a bone mineral density scan (DEXA) under Medicare?

Under RACGP guidelines, Medicare rebates for screening DEXA scans are available for asymptomatic individuals aged 70 years and over. For younger patients, rebates apply if they have secondary risk factors: prolonged glucocorticoid therapy (>=3 months), premature menopause (<45 years), primary hypogonadism, malabsorption disorders (celiac disease), or a history of minimal trauma fracture.

How do we define premature family history of cardiovascular disease?

Premature cardiovascular disease is defined as a first-degree male relative (father or brother) diagnosed with cardiovascular disease (myocardial infarction, stroke, coronary revascularization) under the age of 55, or a first-degree female relative (mother or sister) diagnosed under the age of 65. A premature family history increases a patient’s risk category on the AusCVDRisk calculator.

---

---

Written by the MplusX Editorial Team — dedicated to providing clinically accurate, structured, and practical resources for international medical graduates pursuing licensing with the Australian Medical Council.

References

• John Murtagh‘s General Practice (8th Edition): Chapter 9: A safe diagnostic model, Page 208
• RACGP Red Book (10th edition): Chapter I: Introduction
• Therapeutic Guidelines (eTG): Clinical Prescribing Principles

---

---

---

Reading about MplusX vs AMEDEX might also be helpful.

---

Disclaimer: This article is written for AMC MCQ examination preparation and general informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Clinical decisions should always be based on individual patient assessment, current Australian Therapeutic Guidelines (eTG), and consultation with qualified healthcare professionals. MplusX is an exam preparation platform and is not a substitute for supervised clinical training.